chufangao/CTO huggingface dataset:
Clinical trial NCT03640221: Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.
Official title: A Double-blind, Randomized, Parallel 2- Arm Study to Compare the Efficacy of Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes Who Are Receiving Background Standard-of-care Cardio-metabolic Therapy With Metformin, an Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker, and a Statin.
Acronym: Ertugliflozin
Sponsor: Cedars-Sinai Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Study withdrawn prior to IRB approval and enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-01
Primary completion date: 2020-05-31
Completion date: 2020-08-31
Plan to share individual participant data: NO
Clinical trial NCT04493619: PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Official title: A Multicenter, Open-Label, Parallel, Phase 2a Study of PLX2853 Monotherapy in Advanced Gynecological Malignancies With a Known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer
Sponsor: Opna Bio LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: study terminated due to business realignment
Enrollment: 37.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-11
Primary completion date: 2022-04-25
Completion date: 2022-04-25
Clinical trial NCT02878538: A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment
Official title: An N of One Clinical Trial to Pilot the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment
Sponsor: The University of Texas Health Science Center at San Antonio (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Study was withdrawn before IRB approval
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-31
Primary completion date: 2022-04-30
Completion date: 2023-04-30
Plan to share individual participant data: NO
Clinical trial NCT04811404: A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid
Official title: A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid
Sponsor: New York State Psychiatric Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Reassessment of rationale for study
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-03-19
Primary completion date: 2022-07-01
Completion date: 2022-07-01
Plan to share individual participant data: NO
Clinical trial NCT02263729: Phase 1/2 Prospective Double-Blind Placebo-Controlled Randomized Clinical Trial of Losartan to Treat Grade II & III Hamstring Strains
Official title: Phase 1/2 Prospective Double-blind, Placebo-controlled Randomized Clinical Trial Using Losartan to Treat Grade II and III Hamstring Strains
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was terminated due to difficulty identifying eligible participants and the expiration of funding.
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-08-10
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Limitations and caveats: Recruitment was complicated primarily due to delays in identifying potential study participants, as individuals were often excluded for presenting \> 7 days from injury (n=106), not having at least a grade 2 injury (n=9), or refusing participation (n=9). The study was terminated due to the expiration of funding, which resulted in a sample size of 6 participants. Given this sample size was smaller than anticipated, no between-group significance testing was performed.
Clinical trial NCT05456854: Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp
Official title: Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Futility
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-03
Primary completion date: 2024-08-01
Completion date: 2024-08-01
Plan to share individual participant data: NO
Clinical trial NCT06020664: NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers (NTCDU)
Official title: A Randomized, Placebo Controlled, Evaluator-Blinded Study to Assess the Efficacy and Safety of NOX1416 in the Treatment of Chronic, Non-Healing, Diabetic Foot Ulcers
Acronym: NTCDU
Sponsor: NOxy Health Products, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: The NO-002 study had to be paused because of enrollment disruptions due to the current situation in Israel, and concerns over the placebo batch stability results.
Enrollment: 30.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2023-08-16
Primary completion date: 2024-09-30
Completion date: 2024-11-24
Plan to share individual participant data: NO
Clinical trial NCT02799745: A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance
Official title: A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT)
Acronym: ENACT
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 227.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-09
Primary completion date: 2020-08-28
Completion date: 2020-08-28
Baseline population: The full analysis set (FAS) consisted of all participants who were randomized.
Plan to share individual participant data: YES
IPD sharing description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
IPD time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
IPD access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Clinical trial NCT03364738: Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism
Official title: An Open-label Study Investigating the Safety and Efficacy of rhPTH(1-84) in Subjects With Hypoparathyroidism
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was terminated due to Takeda commercial Natpara recall.
Enrollment: 22.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-09-26
Primary completion date: 2020-04-14
Completion date: 2020-04-14
Baseline population: The safety analysis population consisted of all participants who have received at least 1 dose of rhPTH(1-84).
Limitations and caveats: The study was terminated due to Takeda commercial Natpara recall.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT03425331: Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Official title: Biomarkers of Response to Ipilimumab and Nivolumab as First-line Therapy for Metastatic Non-small Cell Lung Cancer (NSCLC): an Open-label, Single Arm Phase 2 Study
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow accrual, competing studies, and lack of efficacy
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-04-10
Primary completion date: 2020-05-18
Completion date: 2021-11-28
Plan to share individual participant data: NO
Clinical trial NCT00703326: Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
Official title: A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1144.0 (ACTUAL)
Number of arms: 2.0
Start date: 2008-08-06
Primary completion date: 2013-03-31
Completion date: 2020-11-19
Baseline population: Intent-to-Treat (ITT) Population: All randomized participants.
Limitations and caveats: One participant assigned to placebo + docetaxel (doc) treatment and was given ramucirumab (ram) in Cycle 1. Considered ram + doc treatment arm for safety population, for ITT population the participant was analyzed according to assigned treatment.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and european union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT04575584: Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
Official title: A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults With COVID-19
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Business reasons
Enrollment: 304.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-10-19
Primary completion date: 2021-08-11
Completion date: 2021-08-11
Baseline population: No participants were enrolled in Part 2 arms due to early study termination.
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03904316: Use of Biodesign® Otologic Graft in Tympanoplasty
Official title: Use of Biodesign® Otologic Graft in Tympanoplasty: A Prospective, Randomized Trial
Sponsor: Ascension South East Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: The trial was stopped as the benefit was challenging to determine in preliminary usage.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-03
Primary completion date: 2022-07-01
Completion date: 2022-07-01
Clinical trial NCT03938454: A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
Official title: A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
Acronym: SPARTAN
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 36.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-16
Primary completion date: 2023-03-28
Completion date: 2023-11-29
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03414788: Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease
Official title: PHASE 1B, OPEN LABEL STUDY TO CHARACTERIZE THE DISTRIBUTION OF A SINGLE INTRAVENOUS DOSE OF [124I]-IODOBENZOYL (IB)-PF-06687234 WITH CONCURRENT ADMINISTRATION OF NON-RADIOLABELED PF-06687234 AS ASSESSED WITH POSITRON EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY (PET-CT) IMAGING IN MODERATE TO SEVERE ULCERATIVE AND CROHN'S COLITIS SUBJECTS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: The study was withdrawn due to not being able to recruit subjects.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-07
Primary completion date: 2022-02-01
Completion date: 2022-02-01
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04320615: A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia
Acronym: COVACTA
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 452.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-03
Primary completion date: 2020-06-24
Completion date: 2020-07-28
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform https://vivli.org.~Further details on Roche's criteria for eligible studies are available here: https://vivli.org.~For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm
Clinical trial NCT02694393: Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis
Official title: Phase I/II Study of Inhaled Sodium Nitrite as an Antimicrobial for Pseudomonas Infection in Cystic Fibrosis
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Protocol closed due to difficulty recruiting subjects and then expiration of investigational product and lack of a manufacturer.
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-02-29
Primary completion date: 2022-07-21
Completion date: 2022-07-21
Limitations and caveats: The study was terminated early due to expiration of investigational product and lack of a manufacturer.
Plan to share individual participant data: NO
Clinical trial NCT03000179: Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
Official title: Pilot Study to Investigate the Safety and Efficacy of Avelumab Monotherapy in Patients With Advanced or Metastatic Adenocarcinoma of the Small Intestine
Sponsor: Vanderbilt-Ingram Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low accrual
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-03-03
Primary completion date: 2021-08-03
Completion date: 2021-08-03
Plan to share individual participant data: UNDECIDED
Clinical trial NCT01865630: Safety and Efficacy Study of Etanercept for Aneurysmal Subarachnoid Hemorrhage
Official title: Phase I Safety, Blood Brain Barrier Permeability and Potential Efficacy of Etanercept for Aneurysmal Subarachnoid Hemorrhage
Sponsor: Unity Health Toronto (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: PI moved to another institution
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-31
Primary completion date: 2022-01-31
Completion date: 2022-01-31
Plan to share individual participant data: NO
Clinical trial NCT02963051: A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
Official title: A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study stopped due to lack of efficacy.
Enrollment: 9.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-07-11
Primary completion date: 2018-12-30
Completion date: 2020-02-01
Clinical trial NCT02035085: 19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction
Official title: This is a First-in-man, Phase I Study Utilizing 19F Magnetic Resonance Imaging (MRI) to Track Autologous, Adipose Derived Stem Cells.
Acronym: CS-1000
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Drugs/devices discontinued
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-06-30
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Clinical trial NCT04082715: Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity
Official title: Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity
Sponsor: Second Affiliated Hospital of Wenzhou Medical University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: we don't have enough research funding.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-10-31
Primary completion date: 2022-12-31
Completion date: 2023-12-31
Clinical trial NCT03121534: Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
Official title: A Phase II Study of Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was closed for slow accrual
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-06-22
Primary completion date: 2022-02-11
Completion date: 2022-02-11
Clinical trial NCT04331002: Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury
Official title: Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury
Acronym: SLAM
Sponsor: University of Kentucky (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Funding Termination
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-21
Primary completion date: 2022-07-11
Completion date: 2022-07-11
Baseline population: Research cancelled and 0 participants enrolled in Arm 2
Plan to share individual participant data: YES
IPD sharing description: With the participant's approval and as approved by local Institutional Review Boards (IRBs), de-identified biological samples will be stored at the University of Kentucky Orthopedic Biomarker Repository. These samples could be used to research the causes of osteoarthritis after meniscus injury, its complications and other conditions for which individuals with meniscus injuries are at increased risk, and to improve treatment.~Before sharing biomarker samples, we will ensure that the participant has given previous consent to the sharing of the information or samples. When we confirm that the previously provided consent is still in effect we will remove identifiers such as (e.g., name, medical record number, or date of birth). We will use a secure electronic log to track information shared without releasing the individual participant's identity.
IPD time frame: Access to individual participant data will be available 1 year after the final study follow-up has been completed, and will be available until 5 years after the final study follow-up has been completed.
IPD access criteria: The researchers requesting access to participant information or samples must complete a questionnaire describing why they need information or samples for their research and how they will use the information or samples. The researchers who receive the information or samples will sign an agreement to use the data responsibly.
Clinical trial NCT03991000: Iron in Patients With Cardiovascular Disease
Official title: Investigator-initiated, Randomized, Double-blind, Controlled, Multi-center Trial of Intravenous Iron in Patients With Cardiovascular Disease and Concomitant Iron Deficiency
Acronym: iCHF-2
Sponsor: Universitätsklinikum Hamburg-Eppendorf (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Due to poor recruitment largely due to the covid pandemic, no safety concerns.
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-28
Primary completion date: 2021-12-15
Completion date: 2021-12-15
Plan to share individual participant data: NO
Clinical trial NCT01895829: Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI
Official title: Pilot Feasibility Study of Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI for Primary and Nodal Tumor Imaging in Locally Advanced Head and Neck Squamous Cell Carcinomas
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Study halted prematurely and will not resume
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-09-12
Primary completion date: 2021-09-07
Completion date: 2021-09-07
Clinical trial NCT03147040: AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer
Official title: AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer: GELATO-trial
Acronym: GELATO
Sponsor: The Netherlands Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: At interim analysis insufficient benefit was observed to continu the study
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-11-02
Primary completion date: 2022-05-01
Completion date: 2022-07-01
Plan to share individual participant data: UNDECIDED
IPD sharing description: to be decided